Effect of oral immunomodulator Dzherelo in TB/HIV co-infected patients receiving anti-tuberculosis therapy under DOTS.

[1]  N. Sokolenko,et al.  Open label trial of adjuvant immunotherapy with Dzherelo, Svitanok, and Lizorm, in MDR-TB, XDR-TB and TB/HIV co-infected patients receiving anti-tuberculosis therapy under DOT , 2007 .

[2]  N. Boéchat,et al.  Low expression of antigen-presenting and costimulatory molecules by lung cells from tuberculosis patients. , 2007, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[3]  E. Zagaynova,et al.  Comparative effect of an immunomodulator Immunoxel (DzhereloT) when used alone or in combination with antiretroviral therapy in drug-naive HIV-infected individuals , 2007 .

[4]  S. Jolles,et al.  Current strategies in TB immunotherapy. , 2007, Current molecular medicine.

[5]  J. Herrmann,et al.  B-cell immune responses in HIV positive and HIV negative patients with tuberculosis evaluated with an ELISA using a glycolipid antigen. , 2007, Tuberculosis.

[6]  Y. Balabanova,et al.  Molecular epidemiology and prevalence of mutations conferring rifampicin and isoniazid resistance in Mycobacterium tuberculosis strains from the southern Ukraine. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  C. Dye,et al.  Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. , 2006, The Lancet. Infectious diseases.

[8]  B. N. Carvalho,et al.  Peripheral Blood Mononuclear Cells Immunophenotyping in Pulmonary Tuberculosis Patients before and after Treatment , 2006, Microbiology and immunology.

[9]  N. Chentsova,et al.  Tuberculosis-HIV Co-infection in Kiev City, Ukraine , 2006, Emerging infectious diseases.

[10]  S. Kaufmann.  Tuberculosis: back on the immunologists' agenda. , 2006, Immunity.

[11]  I. Çelik,et al.  Lymphocyte Subpopulations in Pulmonary Tuberculosis Patients , 2006, Mediators of inflammation.

[12]  John L. Johnson,et al.  Mycobacterium tuberculosis and human immunodeficiency virus type 1 interaction: Pathogenesis and disease modulation in dual infection , 2014 .

[13]  J. Nkengasong,et al.  Changes in HIV RNA viral load, CD4+ T‐cell counts, and levels of immune activation markers associated with anti‐tuberculosis therapy and cotrimoxazole prophylaxis among HIV‐infected tuberculosis patients in Abidjan, Côte d'Ivoire , 2005, Journal of medical virology.

[14]  P. Dhot,et al.  Comparison of CD4 and CD8 lymphocyte counts in HIV‐negative pulmonary TB patients with those in normal blood donors and the effect of antitubercular treatment: Hospital‐based flow cytometric study , 2004, Cytometry. Part B, Clinical cytometry.

[15]  E. Pérez-Rodríguez,et al.  Impact of tuberculosis on the course of HIV-infected patients with a high initial CD4 lymphocyte count. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[16]  R. Rojas,et al.  Human immunity to M. tuberculosis: T cell subsets and antigen processing. , 2003, Tuberculosis.

[17]  E. Fi.  Use of immunomodulators in viral infections , 2003 .

[18]  R. Salomão,et al.  Immunophenotypic characterization of peripheral T lymphocytes in Mycobacterium tuberculosis infection and disease , 2002, Clinical and experimental immunology.

[19]  J. Flynn,et al.  CD4+ T Cells Are Required for the Development of Cytotoxic CD8+ T Cells During Mycobacterium tuberculosis Infection1 , 2001, The Journal of Immunology.

[20]  R. Nirmala,et al.  Reduced NK activity in pulmonary tuberculosis patients with/without HIV infection: identifying the defective stage and studying the effect of interleukins on NK activity. , 2001, Tuberculosis.

[21]  Khauadamova Gt,et al.  [Special features of the course of tuberculosis in HIV-infected patients]. , 2001 .

[22]  Pokrovskiĭ Vv.  [Treatment of HIV-infections: success or crisis?]. , 2001 .

[23]  K. Elkins,et al.  Infection of B Cell-Deficient Mice with CDC 1551, a Clinical Isolate of Mycobacterium tuberculosis: Delay in Dissemination and Development of Lung Pathology1 , 2000, The Journal of Immunology.

[24]  Karachunskiĭ Ma.  Tuberculosis in HIV infection , 2000 .

[25]  I. Tsuyuguchi.  [Immunotherapy for MDR-TB (multi-drug resistant tuberculosis)--its feasibility]. , 1999, Kekkaku : [Tuberculosis].

[26]  S. Ress,et al.  Reduced NK activity correlates with active disease in HIV patients with multidrug‐resistant pulmonary tuberculosis , 1994, Clinical and experimental immunology.

[27]  G. Scott,et al.  Natural killer cell activity in tuberculosis. , 1985, British journal of diseases of the chest.